ClinicalTrials.gg
RecruitingNCT05999149BCTOP-T-N01Updated Nov 6, 2026

A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)

A Phase 3 interventional study of Camrelizumab Plus Chemotherapy and Famitinib and Camrelizumab Plus Chemotherapy in TNBC - Triple-Negative Breast Cancer, sponsored by Fudan University. Recruiting at 2 sites in China. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Fudan University · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2023; still recruiting 3 years 3 months later.
Updated Nov 6, 2026Primary completion moved2 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
424
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies testing camrelizumab in Triple Negative Breast Neoplasms — 11 open to participants now, 12 under way, 4 of them phase 3. camrelizumab · Triple Negative Breast Neoplasms.

Planned enrollment
4th of 21
424 · median 90
Started
2023
with 3 others
Phase 3
5 of 21
3 open now
Primary completion
2026-05
later than 4 of 11 live
Registered
17th of 21
by date
Lead sponsor
9 of 21
Fudan University

Among the 21 studies testing camrelizumab in Triple Negative Breast Neoplasms, this one is the 4th largest by planned enrollment, is one of 4 that started in 2023, is one of 5 in phase 3, reaches primary completion later than 4 of the 11 other live ones, and was the 17th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

11 of the 21 studies testing camrelizumab in Triple Negative Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

About camrelizumab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 329 Triple Negative Breast Neoplasms studies recruiting now, 229 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing camrelizumab in Triple Negative Breast Neoplasms, or all of them as a file.
02

Study summary

This is an open, randomized, controlled, multicenter Phase III clinical study. Eligible subjects were randomly assigned 1:1 to albumin-paclitaxel plus carboplatin and carrilizumab with or without famitinib neoadjuvant therapy. Stratification was performed at randomization according to the following factor: clinical stage of the tumor (stage II; Stage III) . Subjects who have completed neoadjuvant therapy and are suitable for surgery are required to undergo surgery. Subjects in the experimental group will continue to receive carrilizumab and famitinib until one year from the start of neoadjuvant therapy, and subjects in the control group will continue to receive carrilizumab until one year from the start of neoadjuvant therapy.

Subjects who completed neoadjuvant therapy were required to undergo imaging efficacy evaluation according to RECIST1.1 before surgery; subjects suitable for surgery received surgical treatment, and pathological evaluation of tumor efficacy was performed after surgery.

During the study treatment, if the subjects show disease progression, toxicity intolerance, withdrawal of informed consent, or the investigator determines that medication must be terminated, the study treatment will be terminated, and follow-up will continue, including disease recurrence and metastasis and safety follow-up.

Participants who complete surgical treatment will be followed for at least 2 years for event-free survival (EFS), disease-free survival (DFS), distant metastasis-free survival (DDFS), and safety assessment. Safety data should be collected from the signing of the informed consent until 28 days after the end of the study.

03

Conditions studied

  • TNBC - Triple-Negative Breast Cancer
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Inclusion Criteria:

Performance Status of 0-1. Early or locally advanced, documented TNBC (absence of , ER, and PR expression).

Tumor stage: II-III. Adequate hematologic and organ function. Must be willing to use an adequate method of for the course of the study.

Exclusion Criteria:

  • Has a history of breast cancer. Has a history of invasive ≤5 years prior to signing except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.

Has received prior chemotherapy, targeted therapy, and radiation therapy within the past 12 months.

Has received prior therapy with an anti-programmed cell death protein 1 (), anti-programmed death - ligand 1 (anti-PD-L1), or anti-PD-L2 agent or with an agent directed to another co-inhibitory T-cell receptor (e.g., cytotoxic T-lymphocyte-associated antigen-4 [CTLA-4].

Has a diagnosis of immunodeficiency or diseases. Has received any form of therapy within 4 weeks prior to the first dose of study treatment.

Severe pulmonary or cardiac disease. Known active virus, or known active virus. History of organ or bone marrow transplantation. Pregnant or breast-feeding women. Patients who have previously received VEGFR-like small molecule tyrosine kinase inhibitors (such as famitinib, sorafenib, Sunitinib, regorafenib, etc.) (except bevacizumab); Urine routine indicated urinary protein ≥2+ and confirmed urinary protein quantity > 1g at 24h;

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
424 participants (estimated)

Study arms

  • Experimental
    Arm A

    Camrelizumab Plus Chemotherapy and Famitinib

    Drug: Camrelizumab Plus Chemotherapy and Famitinib

  • Active comparator
    Arm B

    Camrelizumab Plus Chemotherapy

    Drug: Camrelizumab Plus Chemotherapy

Interventions

06

What researchers measure

Primary outcomes

  1. Pathological complete response (pCR) rate

    the definition of ypT0/Tis ypN0 (i.e., no invasive residual in breast or nodes; noninvasive breast residuals allowed) at the time of definitive surgery

    Time frame: Up to approximately 24 weeks

Secondary outcomes

  1. Event-free Survival (EFS) as assessed by Investigator

    EFS is defined as the time from randomization to any of the following events: progression of disease that precludes surgery, local or distant recurrence, second primary malignancy (breast or other cancers) or death due to any cause.

    Time frame: At least 2 years

  2. Disease-free Survival (DFS) as assessed by Investigator

    DFS is defined as the time from surgery to any of the following events: local or distant recurrence, or death due to any cause.

    Time frame: At least 2 years

  3. Distant Disease-free Survival (DDFS) as assessed by Investigator

    DDFS is defined as the time from surgery to distant recurrence, or death due to any cause.

    Time frame: At least 2 years

  4. Objective response rate (ORR) in accordance with RECIST v1.1

    Number of responders Assessed by Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) for target lesions assessed by MRI.

    Time frame: Up to approximately 24 weeks

  5. Number of responders Assessed by Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) for target lesions assessed by MRI.

    Time frame: Up to approximately 67 weeks

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in May 2026, 33 months.

Of 60 phase 3 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 103. This study's 33 months is below that.

Primary completion moved once since we started tracking on Sep 25, 2026: Aug 2025 → May 2026, on Nov 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2023
First posted
Aug 21, 2023
StartActual
Aug 20, 2023
Primary completionActual
May 30, 2026was Aug 2025
CompletionEst.
Aug 30, 2027
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 2 sites removed
Show 2 added (2 China)
  • Breast cancer institute of Fudan University Cancer Hospital · Shanghai, China
  • Fudan University Shanghai Cancer Center Shanghai, China, 200032 · Shanghai, China
Show 2 removed
  • Breast cancer institute of Fudan University Cancer Hospital · Shanghai, China
  • Fudan University Shanghai Cancer Center Shanghai, China, 200032 · Shanghai, China
Nov 6, 2026
Primary completion
Aug 30, 2025→May 30, 2026 (actual)
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    2 sites added, 2 sites removed
    Show 2 added (2 China)
    • Breast cancer institute of Fudan University Cancer Hospital · Shanghai, China
    • Fudan University Shanghai Cancer Center Shanghai, China, 200032 · Shanghai, China
    Show 2 removed
    • Breast cancer institute of Fudan University Cancer Hospital · Shanghai, China
    • Fudan University Shanghai Cancer Center Shanghai, China, 200032 · Shanghai, China
    Primary completion Aug 30, 2025→May 30, 2026 (now actual)
    + 3 other changes: index terms, verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05999149
Lead sponsor
Fudan University
Responsible party
Zhimin Shao (Director of General Surgery of Fudan Shanghai Cancer Center, Fudan University) — Principal investigator
First posted
Aug 21, 2023
Start date
Aug 20, 2023
Primary completion
May 30, 2026
Completion
Aug 30, 2027 (estimated)
Last update
Nov 6, 2026

Study contacts

chen li, MD
Contact
chen_li@fudan.edu.cn
+86-021-64175590

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Camrelizumab · Famitinib

Start the discussion